Our Scientific Advisors
Our Scientific Advisors are Key Opinion Leaders in Infectious Diseases with Serious Unmet Medical Needs
Dr. Erik Dubberke
Dr. Dubberke is a Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is a Hospital Epidemiologist at Barnes-Jewish Hospital and Missouri Baptist Medical Center, and is the Clinical Director of the Transplant Infectious Diseases service at Washington University.
His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridioides difficile infection (CDI). His research has influenced guidelines on the diagnosis, treatment and prevention of CDI. Dr. Dubberke has made both the Clarivate Analytics Highly Cited Researchers and “Best Doctors in America” lists, and he has a clinic dedicated to patients with CDI.
Dr. Mark Wilcox
Dr. Wilcox is a Consultant, Head of Microbiology Research & Development, and Infection Lead of the Leeds NIHR Diagnostic Technologies Medical Technology and In Vitro Diagnostic Co-operative at Leeds Teaching Hospitals NHS Trust (LTHT); a Professor of Medical Microbiology, Sir Edward Brotherton Chair of Bacteriology, at the University of Leeds; the Lead on C. difficile infection for Public Health England; as well as the National Clinical Director, Antimicrobial Resistance & Infection Prevention and Control for NHS England.
He has formerly been the Director of Infection Prevention (4 years), Infection Control Doctor (8 years), Clinical Director of Pathology (6 years) and Head of Microbiology (15 years) at LTHT.
Professor Wilcox is Chair of PHE’s Rapid Review Panel (reviews the utility of infection prevention & control products for the NHS), and is a member of the PHE’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance. Since the COVID-19 pandemic, he is a member of UK Scientific Advisory Group on Emergencies (SAGE, COVID-19; and chairs one of its subgroups on Nosocomial Infection), and as co-chair of the UK Technical Validation Group for COVID-19 tests. He is a member of the Medical Research Council’s Infections and Immunity Board, and the Scientific Advisory Board for the EU Innovative Medicines Initiative’s COMBACTE-NET consortium. From 2017, he was seconded one day per week to NHS Improvement to support the delivery of the new national target to reduce healthcare associated Gram-negative blood stream infections in England. He was the Deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee until 2018.
He is an expert advisor to the Department of Health in England on healthcare associated infections (HCAIs), UK NICE (C. difficile management and antimicrobial evaluations project), the UK EPIC/NICE projects, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection, the Wellcome Trust and CARB-X panel on novel antimicrobials, and the European Centre for Disease Control. He is a member of UK, European and US working groups on C. difficile infection, and is on the Editorial Boards of Clinical Infectious Diseases, Journal of Hospital Infection and Infectious Diseases in Clinical Practice. He has provided clinical advice as part of the FDA / EMA submissions for the approval of several novel antimicrobial agents, 1998-2016.